Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults

Completed · Not applicable

Conditions studied: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

In brief

The purpose of this study is to characterize the impact of acetaminophen ingestion on the performance of the Guardian™ Sensor (3) (i.e., C algorithm and Zeus algorithm) in subjects age 18 - 80 years.

Key facts

Study ID: NCT04378114
Run by: Medtronic MiniMed, Inc.
People needed: 104
Starts: 2020-05-18
Expected to finish: 2020-07-17
Last updated by the study team: 2023-09-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Individual is 18 - 80 years of age at time of enrollment.
Subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6 months duration as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
Subject has adequate venous access as assessed by investigator or appropriate staff.

You may not qualify if…

Subject has history of allergy to acetaminophen or has been told by a health care provider they may not ingest acetaminophen
Subject reports history of liver cirrhosis or liver problems that a health care provider told them they should not use acetaminophen because of liver disorder.
Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by a qualified individual.
Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection).
Subject is actively participating in an investigational study (e.g., drug or device) wherein he/she has received treatment from an investigational study (drug or device) in the last 2 weeks prior to Visit 1. (Please note participation in an observational study is acceptable.)
Subject is female of child-bearing potential and has a pregnancy screening test that is positive.
Subject is female of child-bearing potential and who is sexually active should be excluded if she is not using a form of contraception deemed reliable by investigator.
Subject is female and plans to become pregnant during the course of the study.
Subject is breast feeding.
Subject has a chronic heavy alcohol use as determined by investigator.
Subject has a history of a seizure disorder.
Subject has a hematocrit (Hct) more than 10% below the lower limit of normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents).
Subject has a history of adrenal insufficiency.
Subject is a member of the research staff involved with the study.

Where it is running

AMCR Institue — Escondido, California, United States
Sansum Diabetes Research Institute — Santa Barbara, California, United States
Diablo Clinical Research — Walnut Creek, California, United States
Barbara Davis Center - Adults — Aurora, Colorado, United States
"Atlanta Diabetes Associates — Atlanta, Georgia, United States
Rainier Clinical Research Center, Inc. — Renton, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.